Conquering Diseases

Study Adding An Investigational Immunotherapy To Standard Treatment For Locally-Advanced Non-Small Cell Lung Cancer

Description

Seeking men and women diagnosed with locally-advanced non-small cell lung cancer that can't be treated with surgery for a study of adding an investigational immunotherapy to the standard cancer treatment.

Overview

Participants in this study will be randomly assigned to get the investigational immunotherapy drug in addition to chemotherapy and radiation or chemotherapy and radiation alone. All participants will get the investigational immunotherapy drug for one year following their chemotherapy and radiation treatment.

What we're hoping for

We are studying whether adding an investigational immunotherapy drug to the chemotherapy and radiation treatment reduces the risk of cancer spreading for locally advanced non-small cell lung cancer (NSCLC) that can't be treated with surgery.

Additional Information

ClinicalTrials.gov Identifier: NCT04092283

 Principal Investigator

William  Walsh, MD

UMass Memorial Health Care

 Study Contact

The Cancer  Research Office

508-856-3216

Cancer.research@umassmed.edu

 Location

UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989